APA (7th ed.) Citation

A, B., T, C., K, S., HH, L., W, L., A, A., . . . MA, R. (2026). Open-label phase 1b/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema. The Journal of allergy and clinical immunology, 157(5), 1127. https://doi.org/10.1016/j.jaci.2026.02.034

Chicago Style (17th ed.) Citation

A, Banerji, et al. "Open-label Phase 1b/2 Trial of Navenibart, a Long-acting Plasma Kallikrein Inhibitor for Hereditary Angioedema." The Journal of Allergy and Clinical Immunology 157, no. 5 (2026): 1127. https://doi.org/10.1016/j.jaci.2026.02.034.

MLA (9th ed.) Citation

A, Banerji, et al. "Open-label Phase 1b/2 Trial of Navenibart, a Long-acting Plasma Kallikrein Inhibitor for Hereditary Angioedema." The Journal of Allergy and Clinical Immunology, vol. 157, no. 5, 2026, p. 1127, https://doi.org/10.1016/j.jaci.2026.02.034.